Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

The IAP antagonist Is In Phase III Trials For Head And Neck Cancer

 
• By Sten Stovall

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Brain Scan
Merck will use its expertise in head and neck cancer to advance xevinapant. • Source: Shutterstock

More from Business

More from Scrip